BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10718212)

  • 21. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development.
    Boberg KM; Schrumpf E; Bergquist A; Broomé U; Pares A; Remotti H; Schjölberg A; Spurkland A; Clausen OP
    J Hepatol; 2000 Mar; 32(3):374-80. PubMed ID: 10735605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma.
    Tannapfel A; Sommerer F; Benicke M; Weinans L; Katalinic A; Geissler F; Uhlmann D; Hauss J; Wittekind C
    J Pathol; 2002 Aug; 197(5):624-31. PubMed ID: 12210082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
    Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
    Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
    [No Abstract]   [Full Text] [Related]  

  • 24. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
    Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases.
    Arora DS; Ramsdale J; Lodge JP; Wyatt JI
    Histopathology; 1999 Jun; 34(6):497-501. PubMed ID: 10383693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations of KRAS and TP53 in a minor proportion of Opisthorchis viverrini-associated cholangiocarcinomas in a hamster model.
    Tangkawattana S; Kaewkes S; Pairojkul C; Tangkawattana P; Sripa B
    Asian Pac J Cancer Prev; 2008; 9(1):101-6. PubMed ID: 18439086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
    Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
    Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses?
    O'Connor DP; Kay EW; Leader M; Murphy GM; Atkins GJ; Mabruk MJ
    Diagn Mol Pathol; 2001 Sep; 10(3):190-9. PubMed ID: 11552722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
    Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
    Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
    Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
    Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New p53 mutations in hilar cholangiocarcinoma.
    Tullo A; D'Erchia AM; Honda K; Kelly MD; Habib NA; Saccone C; Sbisà E
    Eur J Clin Invest; 2000 Sep; 30(9):798-803. PubMed ID: 10998080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.
    Skomedal H; Kristensen GB; Nesland JM; Børresen-Dale AL; Tropé C; Holm R
    J Pathol; 1999 Apr; 187(5):556-62. PubMed ID: 10398121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
    Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
    Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes.
    Hughes NR; Pairojkul C; Royce SG; Clouston A; Bhathal PS
    J Clin Pathol; 2006 Oct; 59(10):1073-8. PubMed ID: 16679351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
    Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
    Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand.
    Kiba T; Tsuda H; Pairojkul C; Inoue S; Sugimura T; Hirohashi S
    Mol Carcinog; 1993; 8(4):312-8. PubMed ID: 8280380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.